Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.

Abstract excerpt

Acute myeloid leukemia (AML) is a genetically heterogeneous disease that, even with current advancements in therapy, continues to have a poor prognosis. Recurrent somatic mutations have been identified in a core set of pathogenic genes including FLT3 (25-30% prevalence), NPM1 (25-30%), DNMT3A (25-30%), IDH1/2 (5-15%), and TET2 (5-15%), with direct diagnostic, prognostic, and targeted therapeutic implications....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Clinical Decision-Making
• Share to Disease Management
• Share to Germ-Line Mutation